CytoMed Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for CytoMed Therapeutics (GDTC).

Price Target Range — 3 Quarters

Analyst Consensus

Consensus RatingSpeculative BuyAvg. Consensus PT$5Upside to Avg. PT+467.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 10, 2024	Benchmark	Bruce Jackson	Maintained	Speculative Buy	$5
Jun 11, 2024	Benchmark	Bruce Jackson	Maintained	Speculative Buy	$5
Dec 4, 2023	Benchmark	Bruce Jackson	Maintained	Speculative Buy	$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023

Benzinga Insights

PRO
Benchmark Initiates Coverage On CytoMed Therapeutics with Speculative Buy Rating, Announces Price Target of $5

Benchmark analyst Bruce Jackson initiates coverage on CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy rating and announces Price Target of $5.

Benzinga Newsdesk

Here's How BlackBerry Can Hit $500M In Software Revenue (And Win Over Investors)

Benzinga

CytoMed Therapeutics Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

CytoMed Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023

PRO
Benchmark Initiates Coverage On CytoMed Therapeutics with Speculative Buy Rating, Announces Price Target of $5

Here's How BlackBerry Can Hit $500M In Software Revenue (And Win Over Investors)

People Also Watch

People Also Watch

CytoMed Therapeutics Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

CytoMed Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBenchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PROBenchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PROBenchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023

PROBenchmark Initiates Coverage On CytoMed Therapeutics with Speculative Buy Rating, Announces Price Target of $5

Here's How BlackBerry Can Hit $500M In Software Revenue (And Win Over Investors)

People Also Watch

People Also Watch

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

PRO
Benchmark Initiates Coverage On CytoMed Therapeutics with Speculative Buy Rating, Announces Price Target of $5